# Boceprevir in End Stage Renal Disease (ESRD)

> **NCT02112630** · NA · WITHDRAWN · sponsor: **Columbia University**

## Conditions studied

- Hepatitis C Infection
- End Stage Renal Disease

## Interventions

- **DRUG:** P-IFN alfa 2a
- **DRUG:** P-IFN alfa 2b
- **DRUG:** Ribavirin
- **DRUG:** Boceprevir

## Key facts

- **NCT ID:** NCT02112630
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-05
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Poor enrollment
- **Last updated:** 2015-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02112630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02112630, "Boceprevir in End Stage Renal Disease (ESRD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02112630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*